Massimo Levrero

Q: What Schools Are Affiliated With Massimo Levrero

Massimo Levrero is affiliated with the following schools: University of Milan, University of Parma, University of Brescia, Sapienza University of Rome, University of Cagliari

Massimo Levrero's AcademicInfluence.com Rankings

Massimo Levrero

Computer Science

#7685

World Rank

#8089

Historical Rank

Machine Learning

#2921

World Rank

#2957

Historical Rank

Artificial Intelligence

#3217

World Rank

#3264

Historical Rank

Database

#4741

World Rank

#4924

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Massimo Levrero's Degrees

PhD Computer Science University of Milan
Masters Computer Science University of Milan
Bachelors Computer Science University of Milan

Similar Degrees You Can Earn

Why Is Massimo Levrero Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Massimo Levrero's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage (1999) (948)
Statements from the Taormina expert meeting on occult hepatitis B virus infection. (2008) (784)
The Human Toll Signaling Pathway: Divergence of Nuclear Factor κB and JNK/SAPK Activation Upstream of Tumor Necrosis Factor Receptor–associated Factor 6 (TRAF6) (1998) (658)
Mechanisms of HBV-induced hepatocellular carcinoma. (2016) (605)
The p53/p63/p73 family of transcription factors: overlapping and distinct functions. (2000) (575)
Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells (1994) (565)
Control of cccDNA function in hepatitis B virus infection. (2009) (497)
IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. (2012) (483)
Activation of SAPK/JNK by TNF Receptor 1 Through a Noncytotoxic TRAF2-Dependent Pathway (1997) (472)
Differential roles of p300 and PCAF acetyltransferases in muscle differentiation. (1997) (438)
Viral hepatitis and liver cancer: the case of hepatitis C (2006) (421)
Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function (2009) (405)
Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. (2006) (405)
Regulation of the p300 HAT domain via a novel activation loop (2004) (389)
Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. (2011) (373)
Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. (1990) (334)
The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage. (2005) (332)
DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. (2002) (330)
Two New p73 Splice Variants, γ and δ, with Different Transcriptional Activity (1998) (326)
Long-lasting memory T cell responses following self-limited acute hepatitis B. (1996) (305)
p300 is required for MyoD‐dependent cell cycle arrest and muscle‐specific gene transcription (1997) (302)
Differential regulation of E2F1 apoptotic target genes in response to DNA damage (2003) (288)
Update of the statements on biology and clinical impact of occult hepatitis b virus infection. (2019) (285)
A global scientific strategy to cure hepatitis B. (2019) (253)
Physical Interaction with Human Tumor-derived p53 Mutants Inhibits p63 Activities* (2002) (244)
Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure (2015) (241)
Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope (1994) (233)
Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B (2017) (218)
The hepatitis B virus X gene induces p53-mediated programmed cell death. (1997) (207)
Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. (2007) (182)
Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. (2019) (178)
Induction of Neuronal Differentiation by p73 in a Neuroblastoma Cell Line* (2000) (177)
Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. (2013) (172)
Hepatitis B virus pX activates NF-kappa B-dependent transcription through a Raf-independent pathway (1996) (157)
Resistance to Fas-mediated apoptosis in human hepatoma cells. (1995) (156)
Apoptotic, non-apoptotic, and anti-apoptotic pathways of tumor necrosis factor signalling. (1998) (155)
Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma (2007) (153)
Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants ε and ζ (1999) (149)
p63 and p73 transactivate differentiation gene promoters in human keratinocytes. (2000) (144)
Endothelial activation by angiotensin II through NFκB and p38 pathways: Involvement of NFκB‐inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin (2003) (142)
Control of hepatitis B virus replication by innate response of HepaRG cells (2010) (140)
Ras- and Raf-dependent activation of c-jun transcriptional activity by the hepatitis B virus transactivator pX. (1994) (139)
Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein (2001) (138)
Induction of the DNA-binding activity of c-jun/c-fos heterodimers by the hepatitis B virus transactivator pX (1994) (138)
Reactive Oxygen Intermediates Mediate Angiotensin II-induced c-Jun•c-Fos Heterodimer DNA Binding Activity and Proliferative Hypertrophic Responses in Myogenic Cells (*) (1995) (135)
The hepatitis B virus X protein up‐regulates tumor necrosis factor α gene expression in hepatocytes (1998) (130)
Structure, function and regulation of p63 and p73 (1999) (129)
Transcriptional regulation of miR-224 upregulated in human HCCs by NFκB inflammatory pathways. (2012) (127)
Tumor Necrosis Factor (TNF) Receptor 1 Signaling Downstream of TNF Receptor-associated Factor 2 (1997) (119)
Full-length and truncated versions of the hepatitis B virus (HBV) X protein (pX) transactivate the cmyc protooncogene at the transcriptional level. (1991) (112)
Nuclear Factor kB-independent Cytoprotective Pathways Originating at Tumor Necrosis Factor Receptor-associated Factor 2* (1998) (109)
Extranodal lymphomas associated with hepatitis C virus infection. (1998) (104)
Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B. (2017) (104)
PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation (2017) (93)
Molecular Mechanisms of HBV-Associated Hepatocarcinogenesis (2013) (92)
Herpes Simplex Virus Disrupts NF-κB Regulation by Blocking Its Recruitment on the IκBα Promoter and Directing the Factor on Viral Genes* (2006) (90)
Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants epsilon and zeta. (1999) (89)
Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. (1996) (87)
Replicative and Transcriptional Activities of Hepatitis B Virus in Patients Coinfected with Hepatitis B and Hepatitis Delta Viruses (2010) (84)
A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes (2009) (84)
Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. (2008) (81)
Expression mechanism of the hepatitis B virus (HBV) C gene and biosynthesis of HBe antigen. (1989) (80)
DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest (2002) (80)
In vitro and in vivo synthesis of the hepatitis B virus surface antigen and of the receptor for polymerized human serum albumin from recombinant human adenoviruses. (1985) (79)
Hepatitis B virus X protein transcription activation domains are neither required nor sufficient for cell transformation. (1998) (78)
Vav cooperates with CD28 to induce NF‐κB activation via a pathway involving Rac‐1 and mitogen‐activated kinase kinase 1 (2002) (77)
Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription (2020) (76)
Expression of co‐stimulatory molecules by kupffer cells in chronic hepatitis of hepatitis C virus etiology (1998) (75)
Defective and nondefective adenovirus vectors for expressing foreign genes in vitro and in vivo. (1991) (74)
Viral determinants and host immune responses in the pathogenesis of HBV infection (2002) (73)
hSirT1-Dependent Regulation of the PCAF-E2F1-p73 Apoptotic Pathway in Response to DNA Damage (2009) (72)
IL6 Inhibits HBV Transcription by Targeting the Epigenetic Control of the Nuclear cccDNA Minichromosome (2015) (70)
Trans-activation of epidermal growth factor receptor gene by the hepatitis B virus X-gene product. (1993) (70)
Aiming for cure in HBV and HDV infection. (2016) (67)
Hepatitis B virus X protein transactivates the long terminal repeats of human immunodeficiency virus types 1 and 2 (1990) (67)
The hepatitis B virus (HBV) pX transactivates the c-fos promoter through multiple cis-acting elements. (1993) (66)
Current treatments for chronic hepatitis B virus infections. (2016) (66)
Distribution of three major hepatitis C virus genotypes in Italy. A multicentre study of 49 5 patients with chronic hepatitis C (1995) (65)
Quantitative evaluation of RASSF1A methylation in the non-lesional, regenerative and neoplastic liver (2006) (65)
Fas/Apo1 mutations and autoimmune lymphoproliferative syndrome in a patient with type 2 autoimmune hepatitis. (1997) (65)
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. (2010) (63)
miRNA let-7c promotes granulocytic differentiation in acute myeloid leukemia (2013) (63)
[502] ADEFOVIR AND LAMIVUDINE COMBINATION THERAPY IS SUPERIOR TO ADEFOVIR MONOTHERAPY FOR LAMIVUDINE-RESISTANT PATIENTS WITH HBeAg-NEGATIVE CHRONIC HEPATITIS B (2007) (62)
Herpes simplex virus disrupts NF-kappaB regulation by blocking its recruitment on the IkappaBalpha promoter and directing the factor on viral genes. (2006) (62)
The Hepatitis B Virus HBx Protein Inhibits Caspase 3 Activity* (1998) (61)
Direct‐acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C (2017) (61)
Mapping of B-cell epitopes of the human hepatitis B virus X protein (1990) (61)
Primary effusion Burkitt's lymphoma with t(8;22) in a patient with hepatitis C virus-related cirrhosis. (1997) (60)
Induction of gene expression via activator protein-1 in the ascorbate protection against UV-induced damage. (2001) (60)
A p38-dependent pathway regulates ΔNp63 DNA binding to p53-dependent promoters in UV-induced apoptosis of keratinocytes (2005) (58)
Long-term response to interferon alpha is unrelated to "interferon sensitivity determining region" variability in patients with chronic hepatitis C virus-1b infection. (1999) (58)
Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities (2017) (58)
Antibodies to hepatitis C virus in patients with hepatocellular carcinoma. (1991) (57)
Intracellular localization of full-length and truncated hepatitis C virus core protein expressed in mammalian cells. (1994) (57)
HBV cure: why, how, when? (2016) (55)
Normalization of depressed natural killer activity after interferon-alpha therapy is associated with a low frequency of relapse in patients with chronic hepatitis C. (1993) (55)
HCV core-mediated activation of latent TGF-β via thrombospondin drives the crosstalk between hepatocytes and stromal environment. (2013) (54)
Regulation of E2F4 mitogenic activity during terminal differentiation by its heterodimerization partners for nuclear translocation. (1998) (54)
The p53 Family Protein p73 Provides New Insights into Cancer Chemosensitivity and Targeting (2009) (54)
Ascorbate up-regulates MLH1 (Mut L homologue-1) and p73: implications for the cellular response to DNA damage. (2002) (54)
Chromatin Dynamics of Gene Activation and Repression in Response to Interferon α (IFNα) Reveal New Roles for Phosphorylated and Unphosphorylated Forms of the Transcription Factor STAT2* (2011) (53)
Vav-1 and the IKKα Subunit of IκB Kinase Functionally Associate to Induce NF-κB Activation in Response to CD28 Engagement1 (2003) (53)
IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection (2012) (51)
In vivo activity of the hepatitis B virus core promoter: tissue specificity and temporal regulation (1995) (51)
Detection of the hepatitis B virus (HBV) covalently-closed-circular DNA (cccDNA) in mice transduced with a recombinant AAV-HBV vector. (2017) (50)
Increased rate of thrombin generation in hepatitis C virus cirrhotic patients. Relationship to venous thrombosis. (1995) (49)
Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug users and prison inmates). (2011) (49)
Genome-wide identification of direct HBx genomic targets (2017) (49)
Combining amplicon sequencing and metabolomics in cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy (2018) (48)
Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells. (2004) (47)
Initiation of hepatitis B virus genome replication and production of infectious virus following delivery in HepG2 cells by novel recombinant baculovirus vector. (2008) (47)
MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis. (2006) (46)
Hepatitis B virus X gene product acts as a transactivator in vivo. (1994) (45)
MyoD prevents cyclinA/cdk2 containing E2F complexes formation in terminally differentiated myocytes (1997) (44)
A Role of p73 in Mitotic Exit* (2005) (43)
p73 and p63 sustain cellular growth by transcriptional activation of cell cycle progression genes. (2009) (43)
p73 Is Regulated by Phosphorylation at the G2/M Transition* (2003) (42)
Structural Variations of Vaginal and Endometrial Microbiota: Hints on Female Infertility (2020) (41)
Binding of CDK9 to TRAF2 (1998) (41)
ChIP-on-chip analysis of in vivo mutant p53 binding to selected gene promoters. (2011) (40)
TP63 and TP73 in cancer, an unresolved “family” puzzle of complexity, redundancy and hierarchy (2014) (40)
Ultrasound detection of abdominal lymphadenomegaly in subjects with hepatitis C virus infection and persistently normal transaminases: a predictive index of liver histology severity. (1998) (39)
HBX causes cyclin D1 overexpression and development of breast cancer in transgenic animals that are heterozygous for p53 (2003) (39)
Mitogen‐activated kinase kinase kinase 1 regulates T cell receptor‐ and CD28‐mediated signaling events which lead to NF‐κB activation (2000) (39)
Perspectives and limitations for nucleo(t)side analogs in future HBV therapies. (2018) (37)
Hepatitis B virus (HBV) X gene expression in human cells and anti-HBx antibodies detection in chronic HBV infection. (1990) (37)
Amino‐acid change in the Epstein‐Barr‐virus zebra protein in undifferentiated nasopharyngeal carcinomas from Europe and North Africa (1998) (37)
Adefovir and lamivudine combination therapy is superior to ADV monotherapy for lamivudine-resistant patients with HBeAG-negative chronic hepatitis B (2007) (36)
Relationship between T cell subsets and suppressor cell activity in chronic hepatitis B virus (HBV) infection. (1983) (36)
Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop. (2011) (36)
Targeting p53 and histone methyltransferases restores exhausted CD8+ T cells in HCV infection (2020) (36)
RelA/NF-κB recruitment on the bax gene promoter antagonizes p73-dependent apoptosis in costimulated T cells (2008) (35)
Digestive and Liver Disease (2011) (35)
Characterization of the hepatitis B virus preS/S region encoded transcriptional transactivator. (1992) (35)
Nonsteroidal anti‐inflammatory drug metabolism potentiates interferon alfa signaling by increasing STAT1 phosphorylation (1999) (34)
Non-invasive biomarkers for chronic hepatitis B virus infection management. (2019) (33)
Risk management of HBsAg or anti-HCV positive healthcare workers in hospital. (2001) (32)
Vitamin D Levels and Il28B Polymorphisms are Related to Rapid Virological Response to Standard of Care in Genotype 1 Chronic Hepatitis C (2012) (32)
Significance of anti‐HBx antibodies in hepatitis B virus infection (1991) (31)
p53-paralog DNp73 oncogene is repressed by IFNα/STAT2 through the recruitment of the Ezh2 polycomb group transcriptional repressor (2011) (29)
Challenges to a Cure for HBV Infection (2017) (28)
Immunoregulatory T cells in HBV-induced chronic liver disease as defined by monoclonal antibodies. (1983) (28)
Immunoregulation of the in vitro anti-HBs antibody synthesis in chronic HBsAg carriers and in recently boosted anti-hepatitis B vaccine recipients. (1985) (27)
Reactive Oxygen Intermediates (ROIs) Are Involved in the Intracellular Transduction of Angiotensin II Signal in C2C12 Cells (1995) (27)
Non-Coding RNAs and Hepatitis C Virus-Induced Hepatocellular Carcinoma (2018) (25)
The hepatitis B virus HBx protein inhibits caspase 3 activity. (2013) (24)
Tumor necrosis factor (TNF) receptor 1 signaling downstream of TNF receptor-associated factor 2. Nuclear factor kappaB (NFkappaB)-inducing kinase requirement for activation of activating protein 1 and NFkappaB but not of c-Jun N-terminal kinase/stress-activated protein kinase. (1997) (24)
DNp73α protects myogenic cells from apoptosis (2006) (24)
The HMGA1 protoncogene frequently deregulated in cancer is a transcriptional target of E2F1 (2013) (24)
Vav-1 and the IKK alpha subunit of I kappa B kinase functionally associate to induce NF-kappa B activation in response to CD28 engagement. (2003) (23)
Intravenous natural β-interferon in white patients with chronic hepatitis C who are nonresponders to α-interferon (1998) (23)
116 A multicenter italian study of rescue adefovir dipivoxil therapy in lamivudine resistant patients: A 2-year analysis of 650 patients (2006) (23)
The sodium/iodide symporter NIS is a transcriptional target of the p53-family members in liver cancer cells (2013) (22)
Modulation of intracellular signal transduction pathways by the hepatitis B virus transactivator pX. (1995) (20)
Bisperoxovanadium, a phospho‐tyrosine phosphatase inhibitor, reprograms myogenic cells to acquire a pluripotent, circulating phenotype (2007) (20)
DNp73alpha protects myogenic cells from apoptosis. (2006) (20)
HAPs hepatitis B virus (HBV) capsid inhibitors prevent HBc interaction with the viral minichromosome and selected host cell genes to inhibits transcription and affect cccDNA stability (2014) (19)
Adenosine deaminase, a key enzyme in DNA precursors control, is a new p73 target (2003) (19)
Ribavirin restores IFNα responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes (2015) (19)
EZH2, JMJD3, and UTX epigenetically regulate hepatic plasticity inducing retro-differentiation and proliferation of liver cells (2019) (19)
The histone deacetylase inhibiting drug Entinostat induces lipid accumulation in differentiated HepaRG cells (2016) (18)
Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma. (1994) (18)
Patterns of chronic hepatitis B in Central Italy: a cross-sectional study. (2010) (17)
T-cell subsets in the hyporesponsiveness to hepatitis B surface antigen (HBsAg) and antigen-specific suppressor lymphocytes in chronic hepatitis B virus (HBV) infection. (1985) (17)
The hepatitis B virus X protein transactivation of c-fos and c-myc proto-oncogenes is mediated by multiple transcription factors. (1992) (17)
Who is more likely to respond to dual treatment with pegylated‐interferon and ribavirin for chronic hepatitis C? A gender‐oriented analysis (2013) (16)
The p73 gene is an anti-tumoral target of the RARβ/γ-selective retinoid tazarotene (2004) (16)
Mechanism of action of ribavirin in anti-HCV regimens: new insights for an age-old question? (2013) (15)
Preliminary Evidence for Hepatitis Delta Virus Exposure in Patients Who Are Apparently Not Infected With Hepatitis B Virus (2021) (15)
Infection of circulating and liver infiltrating T cells by hepatitis C virus of different subtypes. (1995) (15)
Identification of a strong enhancer element upstream from the pregenomic RNA start site of the duck hepatitis B virus genome (1991) (14)
Intravenous natural beta-interferon in white patients with chronic hepatitis C who are nonresponders to alpha-interferon. (1998) (14)
E1A stimulates FGF-2 release promoting differentiation of primary endothelial cells (2000) (14)
Targeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro and in vivo model (2018) (13)
Detection of replicative intermediates of viral RNA in peripheral blood mononuclear cells from chronic hepatitis C virus carriers. (1993) (13)
Occult hepatitis B virus infection. (2000) (13)
Characterization of effector cells in lymphocytotoxicity to autologous hepatocytes in HBsAg-positive and autoimmune chronic active hepatitis (CAH). (2008) (12)
The hepatitis B virus X gene product transactivates the HIV-LTR in vivo. (1993) (11)
Hepatitis Delta Virus histone mimicry drives the recruitment of chromatin remodelers for viral RNA replication (2020) (11)
The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro. (2019) (10)
In vitro anti-HBs antibody synthesis from anti-hepatitis B vaccine recipients. (1987) (10)
SUPPRESSOR CELL FUNCTION IN CHRONIC LIVER DISEASE (1983) (10)
Viral and Host Factors in Determining Response of Relapsers with Chronic Hepatitis C to Retreatment with Interferon (1999) (9)
Treatment of chronic hepatitis B: Update of the recommendations from the 2007 (2011) (9)
A survey of chronic hepatitis B patient management practices in the European Union (2010) (9)
Erratum: The transcriptional coactivator yes-associated protein drives p73 gene-target specificity in response to DNA damage (Molecular Cell (2005) 18 (441-459)) (2005) (9)
HBeAg/anti-HBe system and development of primary hepatocellular carcinoma in patients with HBsAg-positive liver cirrhosis. (1983) (9)
Uncoupling of p21 induction and MyoD activation results in the failure of irreversible cell cycle arrest in doxorubicin-treated myocytes. (1997) (8)
Anti capsid drugs HAP12 and AT130 target HBV core protein nuclear functions (2015) (8)
Cyclosporin a in the treatment of autoimmune chronic active hepatitis occurring with or without circulating antibodies against hepatitis C virus (1992) (8)
1010 OPTIB – A MULTICENTER PROSPECTIVE OPEN LABEL STUDY ON TENOFOVIR (TDF) FOR CHRONIC HEPATITIS B PATIENTS WITH SUBOPTIMAL RESPONSE TO ADV OR ADV/LAM TREATMENT (2010) (8)
Hepatitis C Virus (HCV) RNA Determination After Two Weeks of Induction Interferon Treatment Is an Accurate Predictor of Nonresponse: Comparison of Two Treatment Schedules (2001) (8)
Reciprocal antagonism between the netrin-1 receptor uncoordinated-phenotype-5A (UNC5A) and the hepatitis C virus (2017) (8)
Preliminary evidence for hdv exposure in apparently non-HBV-infected patients. (2020) (7)
Induction of Neuronal Differentiation by p 73 in a Neuroblastoma (2000) (7)
In vitro induction of HBsAg-specific CD8 CD11 human suppressor T cells. (1987) (7)
The molecular basis of myocardial hypertrophy. (1994) (7)
Effect of 28 consecutive days lymphoblastoid interferon (alpha-IFN) administration on hepatitis B virus related chronic liver disease. (1986) (7)
Downregulation of miR‐326 and its host gene β‐arrestin1 induces pro‐survival activity of E2F1 and promotes medulloblastoma growth (2020) (7)
Peripheral blood mononuclear cells and regulatory T cells in acute viral hepatitis. (1985) (7)
Uncoupling of p21 induction and MyoD activation results in the failure of irreversible cell cycle arrest in doxorubicin‐treated myocytes (1997) (7)
A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition In Vitro (2020) (7)
Enhanced response to peginterferon-alpha-2a based triple therapy in previously non-responsive chronic hepatitis C: Final results of PRETTY study. (2005) (7)
deltaN-p73 is a transcriptional target of the PML/RARalpha oncogene in myeloid differentiation. (2007) (6)
Host Epigenetic Alterations and Hepatitis B Virus-Associated Hepatocellular Carcinoma (2021) (6)
Chronic cryptogenic hepatitis in childhood is unrelated to hepatitis G virus. (1999) (6)
ΔN-p73 is a transcriptional target of the PML/RARα oncogene in myeloid differentiation (2007) (6)
Prevalence and genomic variability of transfusion transmitted virus in Italian cryptogenic chronic liver disease and healthy blood donors. (2002) (6)
56 SUPPRESSION OF HEPATITIS B VIRUS (HBV) TRANSCRIPTION AND REPLICATION BY SMALL MOLECULES THAT TARGET THE EPIGENETIC CONTROL OF NUCLEAR cccDNA MINICHROMOSOME (2013) (6)
Low-noise, vibrational phase-sensitive chemical imaging by balanced detection RIKE (2015) (6)
Performance of the cobas® HBV RNA automated investigational assay for the detection and quantification of circulating HBV RNA in chronic HBV patients. (2022) (5)
A temperature-conditional mutant of simian virus 40 large T antigen requires serum to inhibit myogenesis and does not induce DNA synthesis in myotubes. (1997) (5)
p53 functional loss, stemness and hepatocellular carcinoma (2020) (5)
Clinical improvement and partial correction of the T cell defects of acquired immunodeficiency syndrome (AIDS) and lymphoadenopathy syndrome (LAS) by a calf thymus acid lysate. (1986) (5)
Guidelines for the treatment of chronic viral hepatitis (1997) (5)
P0529 : Anti capsid drugs HAP12 and AT130 target HBV core protein nuclear functions (2015) (4)
Etiology of and risk factors for transient and persistent aminotransferase elevation in a population of virus-free blood donors: a multicentre study. (2010) (4)
Suppressor T cells role in the unresponsiveness to Candida albicans in chronic mucocutaneous candidiasis. (1985) (4)
The lncRNAs in HBV-Related HCCs: Targeting Chromatin Dynamics and Beyond (2021) (4)
in Cancer Cells α Tumor Necrosis Factor B Activation by κ Mutant p 53 Enhances Nuclear Factor (2007) (4)
Hepatitis B virus and hepatocellular carcinoma: a possible role for the viral transactivators. (1991) (4)
Expression of the c‐myc protooncogene product in cells infected with the hepatitis delta virus (1994) (4)
Proteasome dysfunction as a reversible defect underlying virus-specific CD8 cell exhaustion in chronic hepatitis B (2017) (4)
11 IN VIVO RIBAVIRIN EFFECTS ON INTERFERON STIMULATED GENES TRANSCRIPTIONAL REGULATION INVOLVES CHROMATIN REMODELING AND HISTONE METHYLATION MEDIATED BY THE G9a METHYL-TRANSFERASE (2013) (4)
Expert Consensus Conference. The screening for hepatitis C virus infection in adults in Italy, May 5-6, 2005. (2006) (4)
The p73 gene is an anti-tumoral target of the RARbeta/gamma-selective retinoid tazarotene. (2004) (4)
The scientific basis of combination therapy for chronic hepatitis B functional cure (2023) (4)
UNPHOSPHORYLATED FORMS OF THE TRANSCRIPTION FACTOR STAT 2 * (2011) (4)
371 HAPS HEPATITIS B VIRUS (HBV) CAPSID INHIBITORS AFFECT CORE PROTEIN INTERACTION WITH THE MINICHROMOSOME AND TARGET cccDNA FUNCTION (2013) (3)
Antiphospholipid Antibodies in Chronic Active Hepatitis: Lack of Correlation with Anti-DNA Antibodies (1985) (3)
56 HBX BINDS IN VIVO ON THE HBV MINICHROMOSOME, MODIFIES THE EPIGENETIC REGULATION OF CCC-DNA FUNCTION AND POTENTIATES HBV REPLICATION (2008) (3)
Correction: IL6 Inhibits HBV Transcription by Targeting the Epigenetic Control of the Nuclear cccDNA Minichromosome (2015) (3)
Monitoring of NK-1 and NK-15 subsets and natural killer activity in kidney transplant recipients receiving cyclosporine. (1985) (3)
Ascorbate upregulates MLH 1 ( Mut L homologue-1 ) and p 73 : implications for the cellular response to DNA damage (3)
Antigen specific suppressor T cells from chronic hepatitis B virus (HBV) carriers inhibit the responsiveness to HBsAg of allogeneic high-responder lymphocytes. (1985) (3)
1121 MIR-224 IS A DIRECT TARGET OF HBX AND MODULATES HBV REPLICATION (2011) (3)
Performance of the cobas® HBV RNA Automated Investigational Assay for the Detection and Quantification of Circulating HBV RNA in Chronic HBV Patients (2022) (3)
Review Control of cccDNA function in hepatitis B virus infection q (2009) (3)
OC-14 miR-224 is a direct target of HBx and modulates HBV replication (2011) (2)
A second-generation hepatitis C virus confirmatory test for chronic hepatitis B virus infection. (1992) (2)
78 MODULATION OF THE EPIGENETIC REGULATION OF CCCDNA FUNCTION CONTRIBUTES TO IFNa INHIBITION OF HBV REPLICATION (2009) (2)
Re-treatment of interferon (IFN) plus ribavirin (RBV) nonresponders with peginterferon (PEG-IFN) Alfa-2A (40KD) (Pegasys) plus RBV and amantadine (AMA) or IFN Alfa-2A (Roferon-A) plus RBV and AMA. Interim results of a multicenter randomized study (2003) (2)
[Hepatitis delta virus replication and the role of the small hepatitis delta protein S-HDAg]. (2018) (2)
Pathobiology of Hepatitis B Virus-Induced Carcinogenesis (2016) (2)
Circulating HBsAg/IgM complexes in acute and chronic hepatitis B. (1984) (2)
Truncated pre-S/S proteins transactivate multiple target sequences. (1992) (2)
Interferon-free direct-acting antiviral therapy decreases the rate of hepatocellular carcinoma recurrence in patients with chronic hepatitis C and advanced fibrosis (2017) (2)
Induction oftheDNA-Binding Activity ofc-Jun/c-Fos Heterodimers bytheHepatitis B VirusTransactivator pX (1994) (1)
Occult hepatitis b virus infection and hepatocellular carcinoma development in patients with chronic hepatitis C (2011) (1)
Hepatitis B. (2018) (1)
External validation of the French alpha‐fetoprotein model for hepatocellular carcinoma liver transplantation in a recent unicentric cohort – a retrospective study (2021) (1)
Quantification of the hepatitis B virus cccDNA: evidence-based guidelines for monitoring the key obstacle of HBV cure (2023) (1)
The HBX-DLEU2 LNCRNA Complex Regulates Transcription from the HBV CCCDNA and from Cellular Genes in CIS and in Trans (2016) (1)
Real-time PCR quantification of serum and intracellular HBV DNA and HDV RNA in different subsets of chronic HBV infected individuals (2009) (1)
[2] EPIGENETIC REGULATION OF HBV CCC-DNA FUNCTION (2007) (1)
Targeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro and in vivo model (2018) (1)
Hepatitis B (2018) (1)
HCV Kinetics in IFN-treated patients is related to treatment schedule and to viral genotype (2000) (1)
AIP 1 apoptotic pathway in leukemia cells Treatment with arsenic trioxide ( ATO ) and MEK 1 inhibitor activates the (2004) (1)
SAT-195-The novel HBx mutation F30V correlates with HCC in vivo, hampers HBV replicative efficiency and enhances anti-apoptotic activity of HBx N-terminus in vitro (2019) (1)
Human recombinant adenovirus used to correct a mouse enzyme deficiency (1990) (1)
p 300 is required for MyoD-dependent cell cycle arrest and muscle-specific gene transcription arrest in the G 0 phase , irreversible exit from the cell cycle (2013) (1)
577 REAL-TIME PCR QUANTIFICATION OF SERUM AND INTRACELLULAR HBV DNA AND HDV RNA IN DIFFERENT SUBSETS OF CHRONIC HBV INFECTED PATIENTS (2009) (1)
Modulation of IFN-α signalling by NSAIDs: therapeutic implications in HCV patients (1998) (1)
41 IL6, IL6-INDUCED MIRNAS AND HNF1A/HNF4A AND THE EPIGENETIC CONTROL OF CCCDNA TRANSCRIPTION (2012) (1)
Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells. (2019) (1)
Prevalence and genomic variability of TT virus (TTV) in Italiancryptogenic hepatitis patients and healthy blood donors (2000) (1)
Characterization of the hepatitis B virus transactivators: A possible direct role of the virus in the development of hepatocellular carcinoma (1993) (1)
EZH2 methyltransferase and JMJD3/UTX demethylases are involved in hepatocytic differentiation and liver cancer cells plasticity (2017) (1)
603 A SURVEY OF CHRONIC HEPATITIS B PATIENT MANAGEMENT PRACTICES IN EUROPE (2008) (1)
Erratum: The human toll signaling pathway: Divergence of nuclear factor κb and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6) (Journal of Immunology (1998) 187 (2097-2101)) (2013) (1)
Epigenetic drugs targeting cccDNA-bound chromatin modifying enzymes silence HBV transcription and inhibit viral replication (2014) (1)
miR-122-regulated metabolic circuits: micro-management of lipid metabolism in the human liver (2018) (1)
External validation of the French AFP model for HCC liver transplantation in a recent unicentric cohort. (2021) (1)
P 73-P 53 AIP 1 apoptotic pathway in leukemia (2004) (1)
41 HBV genomes from liver tissue of patients with occult HBV infection show wide range of sequence divergence and normally replicate in vitro (2004) (1)
343 MICRO-RNA SIGNATURE OF HUMAN HEPATOCELLULAR CARCINOMA (HCC) (2008) (0)
Metformin targets a new EZH2-phosphoSTAT3-miRNAs pathway to inhibit lipid droplets accumulation and intracellular inflammation (2015) (0)
Transactivation-deficient oncogenic delta-TA-p73 and DN-p73 proteins are overexpressed in HCCS (2003) (0)
Monitoring of nk 1 and nk 15 subsets and natural killer activity in kidney transplant recipients under cyclosporine treatment (1984) (0)
P190 HBX DIRECTLY MEDIATES DEREGULATION OF SEVERAL NCRNAS IDENTIFIED BY CHIP-SEQ EXPERIMENT (2014) (0)
F-42 OptiB Italian multicenter prospective study on tenofovir in suboptimal responders to ADV or ADV/LAM treatment: 96 weeks results on efficacy and tolerance (2011) (0)
Polycomb protein enhancer of Zeste Homolog 2 (EZH2) protects human hepatocellular carcinoma (HCC) cells from DNA damage response (DDR) associated apoptosis (2014) (0)
DN-p73 regulates NFκB-dependent proliferation and counteracts p53 and TA-p73-induced growth arrest of hepatocytes (2003) (0)
A hyper-glycosylation of HBV surface antigen characterizes immunosuppression-driven HBV reactivation and hinders HBsAg recognition in vitro (2018) (0)
Editor's Note: p73 and p63 Sustain Cellular Growth by Transcriptional Activation of Cell Cycle Progression Genes (2020) (0)
' s response to reviews Quantitative evaluation of RASSF 1 A methylation in the non-lesional , regenerative and neoplastic Title : liver (0)
SAT-165-Identification of chromatin-accessible domains on the host genome and hepatitis B virus mini-chromosome in infected primary human hepatocytes (2019) (0)
Erratum: The hepatitis B virus HBx protein inhibits caspase 3 activity (The Journal of Biological Chemistry (1998) 58 (3566-3570)) (2013) (0)
Targeting p53 and histone methyltransferases restores exhausted CD8+ T cells in HCV infection (2020) (0)
SAT-178 – International coalition to eliminate hepatitis B - progress report (2017) (0)
631 IFN-A/B TARGET GENES REPERTOIRES MODULATED BY EXOGENOUS TYPE I IFN AND BY THE ENDOGENOUS HBV-INDUCED IFN-RESPONSE IN LIVER CELLS (2010) (0)
"Anti-Ia reactivity in sera from patients with chronic active hepatitis (CAH)". (1987) (0)
HBx directly mediates deregulation of several ncRNAs identified by ChIP-Seq experiment (2014) (0)
Epigenetic sylencing and transcriptional regulation of miRNAs modulated in human HCCs (2009) (0)
12 Class I deacetylases inhibitors affect HBV replication by modulating the acetylation status of cccDNA-bound H3 and H4 histones (2003) (0)
Activation of RAF-1/MAPK/(727-Ser) STAT-1 pathway by HCV core protein causes a transcriptional induction of IFN-a inducible-genes (2002) (0)
CS7.3 cccDNA function and HBV replication (2011) (0)
86 Class III and class I histone deacetylases (HDACS) inhibitors cooperate with DNA damaging chemotherapeutic drugs to induce P73-dependent apoptotic pathways in HCC cells (2004) (0)
Advances in Brief Regulation of E 2 F 4 Mitogenic Activity during Terminal Differentiation by Its Heterodimerization Partners for Nuclear Translocation 1 (2006) (0)
Micro-RNA segnature of human hepatocellular carcinoma (2008) (0)
Functional characterization of IFNa/STAT2 direct target genes by ChIP-on-chip analysis (2007) (0)
The activation of the immediate early proliferation dependent genes by pHBx involves the modification of cellular transcription factors (1991) (0)
Recombinant immunoblot assay for hepatitis C virus antibody in chronic hepatitis. (1992) (0)
Differential regulation of sodium/iodide symporter NIS gene promoter by p53, p63 and p73 in human cholangiocarcinoma (CCA) and hepatocellular (HCC) cell lines (2009) (0)
631 CHROMATIN-BASED ANALYSIS REVEALS THE COMPLEXITY OF THE ALPHA-IFN/STAT2 TRANSCRIPTOME AND IDENTIFIES FUNCTIONALLY DISTINCT SUBSETS OF STAT2 DIRECT TARGET GENES (2008) (0)
COMPARATIVE EVOLUTION OF HEMOSTASIS IN ACUTE PROMYELOCYTIC LEUKEMIA AT ONSET AND IN RELAPSE (2005) (0)
Long term treatment of chronic non a non b hepatitis with recombinant alpha 2a interferon r alpha 2a ifn (1988) (0)
243 HBV replication is regulated in vivo through the acetylation status of CCCDNA-bound H3 and H4 histones and is modulated by class I deacetylases inhibitors (2003) (0)
Characterization of the immune response to the hepatitis B virus X protein in acute and chronic HBV infection (1989) (0)
The post-genomic era: workshop on chromatin immunoprecipitation-related techniques (2007) (0)
469 Inactive HBsAg carriers in central Italy. Cross-sectional and initial prospective data of the hep B free observational study (2006) (0)
Activation in Response to CD28 Engagement B κ Functionally Associate to Induce NF- B Kinase κ Subunit of I α Vav-1 and the IKK (2017) (0)
Pan-Aurora Kinase Inhibitor Mk-0457 Synergistically Potentiates Apo2L/Trail Cytotoxicity in Multiple Mieloma Cells Sensitive and Resistant to Bortezomib. (2009) (0)
F-41 Chromatin dynamics of genes repression in response to IFNa reveal new roles for STAT2, phospho-STAT2, histone deacetylases (HDACs) and histone methylation marks (2011) (0)
Genetic and functional analysis of HBV pX mutants from HCC patients (1998) (0)
545 THE P53-PARALOG DNP73 ONCOGENE IS REPRESSED BY α-IFN/STAT2 THROUGH THE RECRUITMENT OF YY1 AND HDAC1 TRANSCRIPTIONAL REPRESSORS (2009) (0)
Metabolic signatures of chronic hepatitis C evolution revealed by transcriptome profiling of virus-specific CD8 cells across different stages of HCV infection (2017) (0)
The activation of a latent HIV genome by HBV involves the ubiquitous transcription factor kB (1991) (0)
Mutant p53 exerts its gain of function through activation of the NF-κB pathway (2005) (0)
Epigenetic changes associated with the induction of vesicular steatosis in an in vitro cellular model (2014) (0)
Metformin targets a phosphoSTAT3-miRNAs pathway to inhibit lipid droplets accumulation and intracellular inflammation in vitro and in vivo (2015) (0)
OC-9 IL6, IL6-induced miRNAs and HNF1α/HNF4α in the epigenetic control of cccDNA transcription (2012) (0)
606 DUAL ROLE OF STAT1/2 TRANSCRIPTION FACTORS IN CONTROLLING CCCDNA TRANSCRIPTION AND HBV REPLICATION (2010) (0)
EZH2, JMJD3, and UTX epigenetically regulate hepatic plasticity inducing retro-differentiation and proliferation of liver cells (2019) (0)
Hepatitis B Virus X Protein Transcription Activation Domains Are Neither Required nor Sufficient for Cell Transformation 1 (2006) (0)
HCV core causes a sustained activation of the mitogenic map kinasesintracellular signalling pathway (2000) (0)
Early intrahepatic recurrence of HBV infection in liver transplant recipients despite antiviral prophylaxis (2023) (0)
Lamivudine/interferon combination therapy prevents the appearance of YMDD mutants in anti-HBE positive chronic hepatitis B: A controlled pilot study (2003) (0)
F-43 A multicenter prospective observational study to evaluate factors influencing efficacy, tolerance and compliance to antiviral tretament with interferon and ribavirin in daily clinical practice (2011) (0)
364 The HBV transcription/replication process is regulated by the recruitment of a HBX/PCAF complex on the HBV CCCDNA minichromosome (2004) (0)
Divergent patterns of hbv-rna and hbcrag levels in untreated chronic hepatitis delta: a large european cross-sectional study (2022) (0)
HBx–DLEU2 lncRNA complex affects transcription of new target promoters (2015) (0)
Characterization of the transactivating properties of the hepatitis B virus (HBV) X protein (1989) (0)
[Immunosuppressive therapy of chronic active hepatitis: results of a long-term follow-up]. (1983) (0)
P0532 : HBx-DLEU2 lncRNA complex affects transcription of new target promoters (2015) (0)
Identification of circulating microRNAs predictive of HCC in DAA-cured HCV-related cirrhosis (2020) (0)
Accumulation of a cellular protein bearing c-myc-like antigenicity in hepatic and non-hepatic delta antigen expressing cells. (1993) (0)
OC-11 STAT1 and STAT2 transcription factors expression is upregulated in HBV replicating cells by distinct mechanisms (2011) (0)
T-25 MC2791, a specific class III HDAC Sirt1 agonist drug, decreases lipids and reactive oxygen species accumulation in an in vitro model of steatosis in differentiated HepaRG cells (2013) (0)
OC-20 IL28B SNPs (rs8099917 and rs8099860) are associated with spontaneous HCV clearance, progression of fibrosis and response to IFN in Thalassemia Major (TM) patients (2011) (0)
Mo1927 Mucosa-Associated Microbiota and Promoter Methylation Status of Genes Involved in Immune Response in Crohn's Disease Patients (2016) (0)
Cooperative effect of class III and class I histone deacetylases (HDACs) inhibitors with DNA damaging anticancer drugs in HCC cells through p53-and p73-dependent-pathways. (2004) (0)
129 IDENTIFICATION OF HBx TARGET miRNAs THAT REGULATE HBV REPLICATION BY ChIP-Seq (2013) (0)
What is the impact of the decrease of hepatitis C virus incidence on the value of current prognostic models for hepatocellular carcinoma? (2020) (0)
[Management of immune checkpoint inhibitors-induced liver toxicity in cancer]. (2020) (0)
Risk factors of aminotransferase elevation in a population of virus-free blood donors: A multicentre Italian study (2008) (0)
15 CONTROL OF HBV REPLICATION BY HEPATOCYTES INNATE RESPONSE (2008) (0)
Targeting p53 and histone methyltransferases to restore fully exhausted CD8+ T cells in human HCV infection before and after DAA-therapy (2020) (0)
[71] THE SIRT! HYSTONE DEACETYLASE REGULATES TAP TRANSCRIPTION AND APOPTOSIS IN RESPONSE TO DNA DAMAGE (2007) (0)
The AP1 Transcription Factor as a Model to Study the Modulation of Intracellular Signalling Pathways by the Hepatitis B Virus Transactivator pX (1994) (0)
[469] FUNCTIONAL CHARACTERIZATION OF ALPHA-INTERFERON/STAT2 DIRECT TARGET GENES BY CHIP-ON-CHIP ANALYSIS (2007) (0)
Genetic contributions to non-alcoholic fatty liver disease (2023) (0)
SHORT TITLE: IL28B SNPs in thalassemia patients i nfected with HCV (2011) (0)
Combining amplicon sequencing and metabolomics in cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy (2018) (0)
HEPATITIS B FORUM NEXT STEPS IN TREATING PATIENTS WITH CHRONIC HEPATITIS B: CAN WE CURE THIS DISEASE? (2014) (0)
51 NF-KB activation via tyrosine phosphorylation of I-KB-alpha results in the selective modulation of the NF-KB transcriptome and activation of progenitor cells markers (2004) (0)
FASAPO1 MUTATIONS AND DEFECTIVE FAS-MEDIATED APOPTOSIS IN A CHILD WITH TYPE 2a AUTOIMMUNE HEPATITIS. (1997) (0)
Genome-wide identification of HBx cellular target genes and transcriptional partners in HBV replicating HCC cells by ChIP-Seq. (2010) (0)
534 EPIGENETIC SYLENCING AND TRANSCRIPTIONAL REGULATION OF MIRNAS MODULATED IN HUMAN HCCS (2009) (0)
OC-22 Suppression of HBV transcription and replication by small molecules that target the epigenetic control of nuclear cccDNA minichromosome (2013) (0)
The hSIRT1 hystone deacetylase regulates TAp73 transcription and apoptosis in response to DNA damage IN HCC cells (2007) (0)
944 HBX interacts with the PCAF acetyltransferase and it is recruited on the HBV CCCDNA to induce a transcriptionally active HBV minichromosome and to activate replication (2003) (0)
Class I deacetylases inhibitors affect HBV replication by modulating the acetylation status of CCCDNA-bound H3 and H4 histones (2003) (0)
Suppressor cell activity and T-cell subsets in multiple sclerosis. (1987) (0)
PA.91 RISK FACTORS FOR TRANSIENT OR PERSISTENT AMINOTRANSFERASE ELEVATION IN A POPULATION OF VIRUS-FREE BLOOD DONORS. A MULTICENTRE ITALIAN STUDY (2008) (0)
21 Transactivation-deficient oncogenic ΔTA-p73 and DN-p73 proteins are overexpressed in HCCs (2003) (0)
954 RISK FACTORS OF AMINOTRANSFERASE ELEVATION IN A POPULATION OF VIRUS-FREE BLOOD DONORS. A MULTICENTRE STUDY (2008) (0)
Hepatitis V virus (HBV) cccDNA mini-chromosome transposase-accessible chromatin by atac-sec in infected primary human hepatocytes (PHHs) (2020) (0)
The Anti-apoptotic and pro-proliferative p53-related DN-p73 protein is expressed in human HCC (2002) (0)
Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial. (2023) (0)
O.170 Characterization and functional analyses of hepatitis B virus (HBV) isolated from liver tissue of patients with occult HBV infection (2006) (0)
Two New p73 Splice Variants, (cid:103) and (cid:100) , with Different Transcriptional Activity (1998) (0)
Mucosa-associated microbiota structure and methylation status of genes involved in the inflammation response in Chron’s disease (2016) (0)
Erratum: The histone deacetylase inhibiting drug Entinostat induces lipid accumulation in differentiated HepaRG cells (2016) (0)
Molecular diagnostics in hepatitis C virus infection: clinical applications. Scientific Committee--"Tecnologie molecolari nella diagnostica delle epatopatie" of the Italian Association for the Study of the Liver-AISF. (1997) (0)
Genome-wide identification of direct HBx genomic targets (2017) (0)
THU-371-Modulation of H3K27 methylation by EZH2 and UTX/JMJD3 small molecules inhibitors impacts on proliferation and differentiation of hepatic progenitor cells and differentiated hepatocytes plasticity (2019) (0)
Combined Treatment with the Mek Inhibitor PD0325901 and Arsenic Trioxide Has Potent Antitumor Activity in Vivo against Human Multiple Myeloma Xenograft Model. (2008) (0)
742 The β-catenin pathway contributes to aberrant DNP73 expression in human HCC (2006) (0)
The hepatitis B virus: Cofactor of AIDS? Interaction between human immunodeficiency virus (HIV) and hepatitis B virus (HBV) at the molecular level (1990) (0)
1283 MC2791, A SPECIFIC Sirt1 AGONIST DRUG, DECREASES LIPIDS AND REACTIVE OXYGEN SPECIES ACCUMULATION IN AN IN VITRO MODEL OF STEATOSIS IN DIFFERENTIATED HepaRG CELLS (2013) (0)
Hepatitis Delta Virus histone mimicry drives the recruitment of chromatin remodelers for viral RNA replication (2020) (0)
18 δNp73 regulates NFκB-dependent proliferation and counteracts p53 and TAp73-induced growth arrest of hepatocytes (2003) (0)
HBx/DLEU2/EZH2 co-regulation of host genes expression in HCC (2018) (0)
765 HCV CORE PROTEIN MODULATES TGF-ß RESPONSES IN AN AUTOCRINE AND PARACRINE MANNER, A NOVEL PARADIGM FOR THE INTERPLAY BETWEEN HOST- AND VIRAL-RELATED CARCINOGENETIC SIGNALS (2011) (0)
F-42 Gender-specific determinants of response in HCV genotype 1 to current SOC with peg IFN and ribavirin in a practice cohort (2012) (0)
497 Transactivation-deficient oncogenic deltata-P73 and DN-P73 proteins are overexpressed in HCCS (2003) (0)
PTPS-03EPIGENETIC SILENCING OF β-ARRESTIN1 AND ITS INTRAGENIC miR-326 CONTROLS MEDULLOBLASTOMA GROWTH (2015) (0)
GS2.1 Indication to start therapy possible, optional and mandatory (2011) (0)
Cytotoxic T Lymphocyte Response to a Wild Type Hepatitis B Virus Epitope in Patients Chronically Infected by Variant Viruses Carrying Substitutions (2003) (0)
840 DNP73 regulates NFKB-dependent proliferation and counteracts P53 and TAP73-induced growth arrest of hepatocytes (2003) (0)
Cancer formation in WAP-HBV-X transgenic animals a new model to study pX oncogenic potential in vivo (1995) (0)
732 EFFICACY AND TOLERANCE OF TENOFOVIR IN SUBOPTIMAL RESPONDERS TO ADV OR ADV/LAM TREATMENT: 96 WEEKS RESULTS OF THE OPTIB ITALIAN MULTICENTER PROSPECTIVE OPEN LABEL STUDY (2011) (0)
870 EPIGENETIC REGULATION OF CELLULAR TARGET GENES BY HBX: A CHROMATIN-IMMUNOPRECIPITATION (CHIP AND CHIP-SEQ) STUDY TO DEFINE THE HBX TRANSCRIPTOME IN HBV REPLICATING HCC CELLS (2010) (0)
Characterization of circulating hepatitis B Virus RNAs in vitro and chronic hepatitis B patients (2022) (0)
OC-10 IL28B genotype, differential expression of intrahepatic interferon-stimulated genes and response to PEG-IFN and ribavirin therapy in an Italian prospective cohort of genotype 1 hepatitis C patients in “real life” (2012) (0)
Innate responses CD 8 + cells B cells CD 4 + cells Adaptive immune responses Interferon alpha hNTCP Nucleos ( t ) ide analogues (2016) (0)
443 HBX-INDUCED REPRESSION OF MIR224 EXPRESSION RELIEVES THE DIRECT INHIBITORY EFFECTS OF MIR224 ON HBV PGRNA TO POTENTIATE HBV REPLICATION (2012) (0)
Characterization of the sequences acitivated by the truncated pre-S/S proteins (1991) (0)
A functional metagenomics investigation of cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy (2018) (0)
HCV genotype and serum 90L levels: Host and virus related factors predict response to a-IFN therapy (1995) (0)
Arsenic Trioxide (ATO) and MEK1 Inhibitor Activate Apoptotic p73 Pathway in Primary Acute Myelogenous Leukemia Blasts. (2005) (0)
Clinical relevance of next generation sequencing on baseline detection of minority resistance associated variants in HCV-1 patients treated with protease inhibitors (2015) (0)
HBV, mitochondrial stress and liver fibrosis: chicken or the egg. (2023) (0)
83 DNP73 IS A DIRECT TARGET GENE OF BOTH GAIN-OF-FUNCTION BETA-CATENIN MUTANTS AND WILD-TYPE DEREGULATED BETA-CATENIN AND COUPLES WNT PATHWAY ACTIVATION TO CHEMIORESISTANCE IN HUMAN HCC (2008) (0)
The p53 family: What implications in human carcinogenesis? (2001) (0)
RNA helicase DDX5 mediates adaptive response to multi-kinase inhibitors in liver cancer (2022) (0)
F-40 Liver expression of IFNa/β direct target genes and treatment outcomes in HCV infection (2011) (0)
Raf-independent pathway . B-dependent transcription through a Hepatitis B virus pX activates NF-kappa (1995) (0)
207 Activation of the P73-P53AIP1 apoptotic pathway in leukemia cells by combining arsenic trioxide (ATO) with MEK1 inhibitor (2004) (0)
Identification ofa Strong Enhancer ElementUpstream fromthe Pregenomic RNA Start SiteoftheDuckHepatitis B VirusGenome (1991) (0)
Comprehensive immunophenotyping reveals profound alterations of T cell subsets in acute decompensation of liver cirrhosis (2022) (0)
Interplay between O-GlcNAc transferase and enhancer of zeste homolog 2 in hepatocellular carcinoma (2020) (0)
1003 INTRAHEPATIC HBV STATUS AFTER 10 YEAR OF SUSTAINED VIRAL SUPPRESION BY LAM: ANALYSIS OF CCCDNA SEQUENCE AND EXPRESSION (2010) (0)
Hepatitis B virus-associated hepatocellular carcinoma is still a matter of concern in the French Caribbean Island of Guadeloupe. (2021) (0)
516 DIFFERENTIAL REGULATION OF SODIUM/IODIDE SYMPORTER NIS GENE PROMOTER BY P53, P63 AND P73 IN HUMAN CHOLANGIOCARCINOMA (CCA) AND HEPATOCELLULAR (HCC) CELL LINES (2009) (0)
T-18 The HBV capsid inhibitors HAPs affect core protein interaction with the minichromosome and target cccDNA function (2013) (0)
310 CHROMATIN DYNAMICS OF GENES REPRESSION IN RESPONSE TO IFNa REVEAL NEW ROLES FOR STAT2, PHOSPHO-STAT2, HISTONE DEACETYLASES (HDACS) AND HISTONE METHYLATION MARKS (2011) (0)
668 STAT1 AND STAT2 TRANSCRIPTION FACTORS EXPRESSION IS UPREGULATED IN HBV REPLICATING CELLS BY DISTINCT MECHANISMS (2011) (0)
[The behavior of the HBeAg-anti-HBe system in chronic hepatitis]. (1983) (0)
The p53-paralog DNp73 oncogene is repressed by α-IFN/STAT2 through the recruitment of YY1 and HDAC1 transcriptional repressors (2009) (0)
c-myc expression in cells infected with hepatitis delta virus. (1993) (0)
In vivo expression of the hepatitis B virus X protein in transgenic mice (1989) (0)
Identification of shuttle protein hnRNPA1 as a modulating factor of circulating hepatitis B Virus RNAs release in chronic hepatitis B patients (2022) (0)
Epigenetic regulation of HBVCCC-DNA function. (2007) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Massimo Levrero?

Massimo Levrero is affiliated with the following schools:

Massimo Levrero's Academic­Influence.com Rankings

Massimo Levrero's Degrees

Similar Degrees You Can Earn

Why Is Massimo Levrero Influential?

Massimo Levrero's Published Works

Published Works

What Schools Are Affiliated With Massimo Levrero?

Massimo Levrero's AcademicInfluence.com Rankings